Breast Cancer Clinical Trial
Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint Analysis
Summary
This study will examine how ctDNA and additional prognostic genomic information in patients with early stage breast cancer might influences patient decision- making regarding systemic therapy options.
Full Description
This study is an electronically delivered, one time cross sectional survey study. The investigators want to understand how patients with triple negative breast cancer at high risk for disease recurrence will prioritize additional benefit over toxicity when considering treatment options, and if their knowledge of ctDNA positivity versus negativity will further shift this balance toward benefit.
Eligibility Criteria
Inclusion Criteria:
Self- reported history of non-metastatic breast cancer
Self- reported history of receiving chemotherapy for breast cancer
Self- reported history of chemotherapy completed at least 6 months ago but no more than 10 years ago
Able to complete an online survey
English speaking
Exclusion Criteria:
N/A
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Indianapolis Indiana, 46202, United States
How clear is this clinincal trial information?